Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis

Man Wang†, Lei Li†, Yannan Xu†, Juan Du‡* and Changquan Ling†*

†School of Traditional Chinese Medicine, Naval Medical University, Shanghai, China, ‡Department of Emergency, Changhai Hospital, Naval Medical University, Shanghai, China

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common diseases and severe problems worldwide because of the global increase in obesity, dyslipidemia, hypertension, and type 2 diabetes mellitus. NAFLD includes a wide spectrum of liver diseases, the histological forms of which range from non-alcoholic fatty liver (NAFL), which is generally nonprogressive, to non-alcoholic steatohepatitis (NASH), which can progress to chronic hepatitis, liver cirrhosis (LC), and sometimes hepatocellular carcinoma (HCC). Unlike NAFL, as the progressive form of NAFLD, NASH is characterized by the presence of inflammation with or without fibrosis in addition to hepatic steatosis. Although it is widely known and proved that persistent hepatic injury and chronic inflammation in the liver activate quiescent hepatic stellate cells (HSCs) and lead to hepatic fibrosis, the three-step process of "inflammation-fibrosis-carcinoma" in NAFLD has not been investigated and clarified clearly. In this process, the initiation of inflammation in the liver and the function of various liver inflammatory cells have been discussed regularly, while the activated HSCs, which constitute the principal cells responsible for fibrosis and their cross-talk with inflammation, seem not to be investigated specifically and frequently. Also, accumulated evidence suggests that HSCs can not only be activated by inflammation but also participate in the regulation of liver inflammation. Therefore, it is necessary to investigate the unique roles of HSCs in NAFLD from the perspective of inflammation and fibrosis. Here, we review the pivotal effects and mechanisms of HSCs and highlight the potential value of HSC-targeted treatment methods in NAFLD.

KEYWORDS
nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic stellate cells, inflammation, fibrosis

Introduction

Non-alcoholic fatty liver disease (NAFLD), including two subtypes of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), is increasingly prevalent and represents a growing challenge in terms of prevention and treatment (Chalasani et al., 2018). For defining NAFLD, there must be evidence of hepatic steatosis, either by imaging
or histology, and lack of secondary causes of hepatic fat accumulation such as significant alcohol consumption, long-term use of a statin drug, or monogenic hereditary disorders (Tsujisaki et al., 2022). NAFLD is a nonprogressive form of NAFLD in which fat accumulates in the liver but little or no inflammation or liver damage occurs. NAFL generally does not progress to cause liver damage or complications. NASH is a chronic and progressive liver disease which can progress to cirrhosis, liver failure, and rarely liver cancer. NASH is characterized by the presence of >5% HS with inflammation and hepatocyte injury (ballooning) with or without fibrosis. According to the latest epidemiological survey, NAFLD will soon surpass chronic hepatitis virus infection as the primary cause of liver transplantation (Sayiner et al., 2016). Due to the lack of effective therapies for NAFLD, costs of care and management of associated symptoms come with a sizable economic burden (Allen et al., 2018; Estes et al., 2018).

Hepatic stellate cells (HSCs) comprise approximately 1.4% of the total liver volume and represent 5–8% of all liver cells. HSCs are typically located in the perisinusoidal space of Disse, a recess between endothelial cells of sinusoids and hepatocytes (Tacke and Weiskirchen, 2014). Upon liver injury, HSCs are activated, lose lipid-rich granules, and are transdifferentiated into a-smooth muscle actin (a-SMA)-positive myofibroblasts, which produce increased amount of ECM, proinflammatory, and profibrogenic cytokines, and cause liver fibrosis (Kamm and McComnis, 2022).

As a result, the role of HSC activation in liver fibrosis has been widely accepted and draws much attention. However, according to the view in the current studies, HSCs appear to respond to inflammatory signaling from the sinusoids. Whether and how HSCs participate in hepatic inflammation have not been examined in NAFLD. HSCs from both humans and rodents produce cytokines and chemokines upon aberrant stimuli such as lipopolysaccharide (LPS) and other toxic substances, suggesting they can potentially regulate hepatic immune and inflammatory responses through their own gene expression (Fujita and Narumiya, 2016). However, whether HSCs take part in the development of liver inflammation, and if so, whether they take on pro- or anti-inflammatory roles, is still controversial (Fujita and Narumiya, 2016). We will review the pivotal effects and mechanisms of HSCs from the perspective of inflammation and fibrosis, and highlight the potential value of HSC-targeted treatment methods in NAFLD.

Natural history and pathogenesis of NAFLD

Clinically, NAFLD develops in four main stages (Powell et al., 2021). The main stages of NAFLD are: 1) Fat accumulation in the liver cells (steatosis), largely harmless, may be detected only during tests for another reason and this period tends to be termed as NAFL stage. 2) NASH, a more serious form of NAFLD, in which the liver has become inflamed. 3) Fibrosis, which causes scarring around the liver and nearby blood vessels, but the liver is still able to function normally. 4) Cirrhosis is the most advanced stage of the disease, caused by years of inflammation, in which the liver shrinks and becomes scarred and lumpy. It can take many years for fibrosis or cirrhosis to cause permanent damage to the liver, which can lead to liver failure or liver cancer. The majority of people only experience the first stage, which is often not noticed. In a few cases, however, the disease can progress and lead to liver damage if it is not treated. The natural history of patients with NAFLD has been studied for the past several decades (Cohen et al., 2011). Those with histological NASH, especially with some degree of fibrosis, are at a higher risk of suffering adverse outcomes such as cirrhosis and death from liver disease. The prevalence of NASH in NAFLD is estimated at 20%, and up to 20% of these patients may develop cirrhosis over the next 3–4 decades (Singh et al., 2015). Therefore, HCC screening and surveillance is routinely recommended in patients with NASH-related cirrhosis by many guidelines and associations.

NAFLD is primarily caused by overnutrition, which causes the accumulation of ectopic fat and expansion of adipose deposits. NAFLD is often associated with adipocyte enlargement and consequent macrophage recruitment and inflammation. The activation of macrophages in the visceral adipose tissue compartment creates an inflammatory state that leads to insulin resistance. Due to insulin resistance, lipolysis results in fatty acids being unabatedly delivered to the liver, which, combined with increased de novo lipogenesis, overwhelms its metabolic capabilities. When lipid metabolism is skewed, lipotoxic lipids can form, leading to cellular stress, activation of the inflamasomes, and apoptotic cell death. This promotes inflammation, tissue regeneration, and fibrogenesis in the body (Powell et al., 2021). In recent years, the “two-hit” hypothesis has been put forward as an explanation of NASH pathogenesis (Tariq et al., 2014). Based on this theory, NASH is not developed solely as a result of steatosis, but from an additional hit due to other factors including various cellular stress as mentioned previously. Nevertheless, this viewpoint is considered outdated now. NASH is a complex disease with many molecular pathways contributing to its development, and it is still unclear whether NASH is always preceded by NAFL. In addition, pathogenic drivers are unlikely to be identical across all patients. Therefore, both pathogenesis of disease and its clinical manifestations are highly heterogeneous (Friedman et al., 2018). There is now a widely accepted theory known as “multiple-hit,” in which genetics and environment combine to cause more widespread metabolic dysfunction as well as changes in cross-talk among several organs and tissues, including adipose tissue, the pancreas, the gut, and the liver (Fang et al., 2018). In the pathogenesis of NAFLD and its progression, several questions remain unclear. The initial “two-hit” theory cannot explain the pathogenesis of NAFLD in its entirety as it involves multiple factors. Nevertheless, fibrosis
in the liver is mediated by the activation of HSCs and release of extracellular matrix (ECM) associated with hepatocyte injury and inflammation. A driving force behind hepatic fibrosis is inflammation in the liver. Also, the subsequent deleterious effects and mechanisms are worth more investigation in the pathogenesis of NAFLD.
Inflammation and fibrosis in NAFLD

NASH, a progressive form of NAFLD, is characterized by liver steatosis, inflammation, hepatocellular injury, and fibrosis of different degrees. Also, NASH, characterized by the presence of 5% steatosis and inflammation with hepatocyte injury, has an increased liver-related mortality rate according to relevant studies (GBD 2015 Mortality and Causes of Death Collaborators, 2016; Sayiner et al., 2016). As a result of hepatocyte injury followed by inflammation, activation of the innate immune system, and release of extracellular matrix, liver fibrosis is induced. Therefore, understanding these mechanisms of inflammation and fibrosis will enable the design of targeted therapies that can halt or reverse NAFLD progression.

Prior to all symptoms, inflammation is a key pathophysiological mechanism and a target for therapeutic intervention. In view of the most obvious difference between NAFL and NASH, the key issue in this area is the identification of those factors that cause inflammation, thus fueling the transition from simple fatty liver to inflammatory fatty liver (see Figure 1). Since the liver is responsible for the metabolism of lipids and glucose, liver inflammation is closely associated with metabolic disorders such as NAFLD. De novo lipogenesis, reduced B oxidation, and a decreased VLDL cause steatosis in liver cells.

Steatosis is characterized by the accumulation of triglycerides (TGs) as a compensatory response to an increase in free fatty acids (FFAs) within the cell. Moreover, the FFAs are partitioned into an inert and stable lipid, preventing the injury of hepatocytes (Kawano and Cohen, 2013; Brankovic et al., 2022). As a matter of fact, there have been abundant reviews of the mechanisms underlying steatosis development elsewhere. Hence, this article focuses on factors that promote and sustain hepatic inflammation in NAFLD, and attempts to summarize the functional links and key pathways in this process. According to previous investigations, multiple and various factors could act simultaneously, sequentially, or with different hierarchies in NAFLD over time. Also, clinical and pathological characteristics of NAFLD are determined by these complex factors, which include both extrahepatic and intrahepatic effects. Therefore, the roles of these factors would be clarified from intrahepatic and extrahepatic angles. Intrahepatic factors in NAFLD encompass a variety of hepatocellular stress, hepatocellular death, nuclear receptors, and proteins expressed by the liver, innate immunity, genetics, and epigenetics of heritability (Lotze et al., 2007; Wagner et al., 2011; Wree et al., 2013; Luedde et al., 2014; Foroughi et al., 2016; Magee et al., 2016; Meex and Watt, 2017; Eslam et al., 2018), while extrahepatic factors in NASH mainly include dysregulated hepatic glucose, lipid metabolism, and the gut microbiota or the so-called gut–liver axis (Samuel and Shulman, 2012; Brandl and Schnabl, 2017; Caussy et al., 2019). In summary, the liver has to respond to a variety of signals that arrive from adipose tissue and the gastrointestinal tract. For example, as visceral adipose tissue increases, M1 macrophages are infiltrated, which exacerbates insulin resistance and adipose tissue inflammation and causes an altered adipokine profile. As a result of adipose tissue lipolysis, visceral adipose tissue macrophages secrete chemokines and cytokines that induce liver inflammation and IR. Increased FFA levels in the blood cause hepatic lipotoxicity and cell death. Dietary factors can exacerbate inflammation in the liver through a variety of mechanisms, including lipotoxic effects, mitochondrial dysfunction, oxidative stress, and apoptosis. The loss of the gut barrier leads to a higher bacterial translocation and circulating levels of pathogen- or microorganism-associated molecular patterns (P/MAMPs) that can initiate an inflammatory response. The risk of developing NASH is also determined by genetic and epigenetic factors. Inflammation can be resolved by a shift from M2 macrophages to specialized proresolving mediators. The transitions from NAFLD to NASH can be triggered by intrahepatic or extrahepatic factors. Moreover, a variety of inflammatory cells, including hepatic macrophages, T- and B-lymphocytes, NK cells, and platelets, as well as key effectors, such as cytokines, chemokines, and damage-associated molecular patterns, also participate in the process of inflammation in NAFLD. Due to their complex links to HSCs and key pathways related to fibrosis, these significant topics would be discussed later (Schuster et al., 2018).

It is also worth noting that NASH is characterized histologically by fibrosis as the only predictor of clinical outcome (Dulai et al., 2017; Sanyal et al., 2019). As mentioned previously, fibrosis in the liver is mediated by the activation of hepatic stellate cells in response to hepatocyte injury, inflammation, and activation of the innate immune system. The accumulation of extracellular matrix in the liver is the main cause of liver failure and death in patients with NAFLD due to fibrosis and cirrhosis. Fibrogenesis is triggered by signaling from stressed or injured hepatocytes as well as activated macrophages. This causes resident HSCs to become myofibroblasts to produce matrix proteins faster than they are degraded. HSCs are activated as a result of the inflammatory activity of liver immune cells, predominantly macrophages. TGF-B1 derived from macrophages triggers the activation of fibroblasts and is the strongest fibrogenic stimulant known (Hellerbrand et al., 1999). Furthermore, macrophages in the liver, including Kupffer cells and recruited macrophages, are capable of enhancing liver fibrosis by promoting the survival of HSCs. Then, it can be obviously considered that the cellular source of fibrosis in NASH is the hepatic stellate cell (Tsuchida and Friedman, 2017). Therefore, it is necessary to investigate the unique roles of HSCs in NAFLD from the perspective of inflammation and fibrosis.
Roles of hepatic stellate cells in NAFLD: Crosstalk between inflammation and fibrosis

Although the three-step process of “inflammation-fibrosis-carcinoma” in NAFLD has not been investigated clearly, the significance of inflammation and fibrosis can never be ignored at any time. As the foregoing, a variety of cell types including hepatocytes, sinusoidal endothelial cells, inflammatory cells, and hepatic stellate cells participate in the process of deterioration from NAFL to NASH and even cirrhosis and liver cancer. Based on this, HSCs have pivotal effects in NAFLD and relevant mechanisms could help clarify the intricate cross-talk between inflammation and fibrosis.

As a subpopulation of liver cells, HSCs perform numerous critical functions in a healthy liver and in response to injury. Hepatic stellate cells maintain a quiescent state in which they store retinoids and vitamin A-containing metabolites in the absence of liver injury. Some less-appreciated functions of HSCs include amplifying the inflammatory response to liver injury, releasing growth factors that are critical for liver development, and liver regeneration. Therefore, HSCs could be classified into two subtypes, the quiescent HSCs and activated HSCs according to their functional statues (Kamm and McCommis, 2022). However, once HSCs were activated by liver injury such as NASH, differentiation from adipogenic to myofibroblast phenotype with the loss of lipid droplets and expression of contractile fibers, increased cell proliferation, increased HSC chemo taxis as well as signaling to attract leukocytes, and development of matured rough endoplasmic reticulum to support the production of extracellular matrix fibers and matrix remodeling enzymes would be detected from HSCs. While this review does not focus on HSC activation and fibrogenesis, there are many classic reviews available elsewhere on this topic (Friedman, 2000; Bataller and Brenner, 2005; Fujita and Narumiya, 2016; Zisser et al., 2021). Alternately, investigating the unique roles of HSCs in NAFLD is necessary. HSC activation and fibrosis are considered key factors that lead to NAFLD progression. Numerous mechanisms have been proposed for the progression of simple steatosis into NASH and NASH-associated fibrosis. From liver inflammation to fibrosis, HSCs could be triggered by numerous intrahepatic and extrahepatic factors produced by the body immune system through inflammatory response. Quiescent HSCs are located in the space of Disse, a perisinusoidal space between hepatocytes and liver sinusoidal endothelial cells, storing vitamin A in lipid droplets, which represent the major vitamin A storage site for humans (Bataller and Brenner, 2005). PPARγ, adiponectin receptor 1, perilipin 2 (PLIN2/ADFP), C/EBPα, C/EBPB, and SREBP-1c are all expressed by HSCs (She et al., 2005; Kisseleva et al., 2012). Moreover, activated HSCs are a major source of ECM production in liver fibrosis caused by NASH, and are also responsible for liver inflammation induced by cytokines. On one hand, the activation of HSCs results from inflammatory activity of liver immune cells, which has been introduced earlier. The activation of HSCs in obesity is also mediated by leptin, an adipocyte-derived hormone (Potter et al., 2003). Through portal circulation, gut microbes easily enter the liver, activating toll-like receptors (TLRs) in liver cells, TLR4 in particular (Ganz and Szabo, 2013). Numerous reports have highlighted the importance of TLR4, which is a receptor for LPS. Serum levels of LPS are elevated in patients with NASH and animal models of NASH, suggesting that TLR4 is activated (Cani et al., 2007; Miele et al., 2009). The downregulation of transforming growth factor (TGF)-B pseudoreceptor BAMBI also occurs in HSCs by TLR4 ligation, resulting in increased expression of ECM by HSCs (Seki et al., 2007). What is noteworthy is that activated HSCs can also contribute to liver inflammation by secreting cytokines (Wang et al., 2017; Schuster et al., 2018). According to several research studies, HSCs can express multiple toll-like receptors which could also be induced by inflammation (Peveril et al., 2014; Seki and Schwabe, 2015). According to research on the transcription regulation of NASH, it is also reported that the transcriptional dynamics of HSCs are highly similar across diseases, suggesting HSC activation as a point of convergence during the development of NASH (Marcher et al., 2019). Also, this activation could induce the effects on inflammation by the transcriptional regulators ETS1 and RUNX1. Another research study found that HSCs could be regulated by the CD8+ T cells and promote the proliferation of this kind of immune cells, which were highly associated with inflammation in the liver of NASH patient (Breuer et al., 2020).

Renin angiotensin system (RAS) is an essential hormone system that regulates blood pressure and maintain fluid homeostasis (Simões et al., 2017). Also, the components of RAS are present locally in the liver as well. It has been reported that NAFLD has been linked to the activation of RAS both in circulation and locally in the liver (Vergniol et al., 2011; Yang et al., 2020). RAS involved two pathways: one is the classical pathway, which consists of angiotensin converting enzyme (ACE)—angiotensin II (Ang II)—angiotensin II type 1 receptor (AT1R), ACE/AngII/AT1R. ACE plays a crucial role in the classic RAS pathway, in which it converts AngI into AngII, and AngII mediates its biological effects mainly through receptor type 1 (AT1). It has been proved that the activation of this cascade can upregulate the level of TNF-α and TGF-β, which can activate HSC by paracrine and promote the development of NAFLD (Browning and Horton, 2004). In addition, large amounts of AngII are known to increase intracellular ROS leading to the accumulation of lipid peroxidation end-product aldehydes, such as MDA and 4-HNE, which can also convert qHSC into aHSC. Research studies indicated that activated HSCs highly expressed ACE and AT1R in the liver injuries both in vivo and vitro (Wei et al., 2009; Shim et al., 2018). Apart from that, angiotensin converting enzyme2 (ACE2), angiotensin1-7 [Ang...
Mas receptor (MasR) constitute the ACE2/Ang-1-7/MasR axis. ACE2, a homologue of ACE, has the opposite effect of ACE. It can inhabit the synthesis and the bioavailability of AngII, increase its degradation, and form Ang-1-7, which binds to Mas receptors playing the antagonistic roles of the ANG II/AT1 signaling axis, such as actively reducing blood pressure, inhibiting inflammation, proliferation, and fibrosis. It has been proved that Ang (1-7) reduced HSC activation associated with downregulating TGF-β (Rajapaksha et al., 2019; Yang et al., 2020). Thus, the balance between ACE and ACE2 is of considerable importance for homeostasis in the body, especially the development of NAFLD (see Figure 2). Glucagon-like peptide 1 (GLP-1) receptor agonist has dual effects on two axis of RAS, countering ACE/AngII/AT1R axis while activating ACE2/Ang1-7/Mas axis. This suggested potential therapeutic effect in NAFLD. Semaglutide and liraglutide, both GLP-1 receptor agonists, are being tested in the treatment of NAFLD (Potts et al., 2015; Htike et al., 2017; Newsome et al., 2021). Tirzepatide and BI456906 (ClinicalTrials.gov identifier: NCT04771273), dual glucose-dependent insulinotropic polypeptide (GIP) receptor, and GLP-1 receptors agonist compare favorably with the existing GLP-1 receptor agonists in terms of controlling blood sugar levels and weight (Hartman et al., 2020). Some clinicians also indicate that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can delay NAFLD progression (Toblli et al., 2008). ACE inhibitor enalapril and AT1R inhibitor losartan can alleviate liver fibrosis in NAFLD patients with hypertension by inducing the activation of HSC (Yoshiji et al., 2009; Goh et al., 2015). In addition, providing

![Figure 2: Effect of renin angiotensin systems in NAFLD. Two RAS axes, ACE/AngII/AT1R and ACE2/Ang (1–7)/MasR, are illustrated. The former can promote the progression of NAFLD, while the latter plays the opposite role. GLP-1 receptor agonist exerts its therapeutic effect by regulating the balance between them. RAS: renin angiotensin systems; ACE: angiotensin-converting enzyme; AngII: angiotensin II; AT1R: angiotensin II type1 receptor; Ang (1–7): angiotensin1-7; Mas R: Mas receptor; GLP-1: glucagon-like peptide 1.](image-url)
Fig. 3 Switch of HSC phenotypes in NAFLD. Risk factors involved in the progression of NAFLD activate the HSCs and cause a sequence of changes in their features, phenotypes, and functions. These contribute to fibrogenesis and inflammation in the liver, which can promote the activation of HSCs in turn and create a vicious cycle. Thus, regulating the apoptosis of activated HSC and its reversion to inactivated phenotype through various means is the critical resolution of NAFLD. HSC: hepatic stellate cell; NAFLD: non-alcoholic fatty liver disease; PPARγ: peroxisome proliferator-activated receptor γ; GFAP: glial fibrillary acidic protein; BAMBI: bone morphogenetic protein and activin membrane bound inhibitor; PDGFRβ: platelet-derived growth factor receptor β; αSMA: α-smooth muscle actin; FN: fibronectin; LOX: lysyl oxidase; TIMP1: tissue inhibitor of metalloproteinase 1; S100A6: S100 calcium-binding protein A6.
| Medication                          | Primary mechanism      | Trial number       | Major inclusion criteria                                                                 | Outcome(s)                                                                                          | Status                                                                                      |
|------------------------------------|------------------------|-------------------|------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Pioglitazone                       | PPARδ agonist          | NCT00063622       | Patients with NASH and without diabetes                                                   | No benefit of pioglitazone over placebo in fibrosis score (34% and 19%, respectively; \( p = 0.04 \)) | Phase 3; recruitment status: completed                                                     |
| Pioglitazone                       | PPARδ agonist          | NCT00227110       | Patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed NASH | Improvement in metabolism and histological features                                               | Phase 4; recruitment status: completed                                                     |
| Elafibranor                        | PPARα and PPARβ/δ agonist | NCT02704403     | Patients with NASH and fibrosis                                                           | No significant difference in the improvement of fibrosis between treatment and placebo groups       | Phase 3; recruitment status: terminated (study did not meet the predefined primary surrogate efficacy endpoint, no safety issues identified) |
| Lanifibranor                       | PPARα, PPARγ and PPARβ/δ agonist | NCT03008070 | Patients with noncirrhotic, highly active NASH                                              | Significant decrease of at least two points in the SAF-A score without worsening of fibrosis with the 1200-mg dose of lanifibranor than with placebo | Phase 2; recruitment status: completed                                                     |
| Solensertib (STELLAR 3)            | ASK-1 inhibitor         | NCT03053050       | Patients with NASH and bridging fibrosis (F3, STELLAR-3)                                  | No antifibrotic effect                                                                           | Phase 3; recruitment status: terminated (this study was terminated early due to the lack of efficacy based on the results of the week 48 analysis as specified in the clinical study protocol.) |
| Solensertib (STELLAR 4)            | ASK-1 inhibitor         | NCT03053063       | Adults with compensated cirrhosis (F4, STELLAR-4) due to NASH                             | No antifibrotic effect                                                                           | Phase 3; recruitment status: terminated (this study was terminated early due to the lack of efficacy based on the results of the week 48 analysis as specified in the clinical study protocol.) |
| Pentoxifylline                     | PDE4 inhibitor          | NCT04977661       | Egyptian NASH patients                                                                   | Safe and effective in improving liver aminotransferases, serum cytokine, and chemokine in Egyptian NASH patients | Phase 4; recruitment status: completed                                                     |
| ASP9831                            | PDE4 inhibitor          | NCT00668070       | NASH and elevated serum ALT levels                                                        | No significant difference in altering the biochemical markers of NASH, compared to placebo        | Phase 2; recruitment status: completed                                                     |
| Rolflumilast                       | PDE4 inhibitor          | NCT01703260       | Patients with a historical diagnosis of NASH                                              | No results available                                                                            | Phase 2; recruitment status: terminated (company decision; no safety or efficacy concerns) |
| Emricasan                          | Caspase inhibitor       | NCT02686762       | Patients had definite NASH and NASH CRN fibrosis stage F1-F3                             | No improvement in liver histology in patients with NASH fibrosis and with the possibility of worsening fibrosis and ballooning | Phase 2; recruitment status: completed                                                     |
| Emricasan                          | Caspase inhibitor       | NCT02960204       | Patients with NASH-related cirrhosis and baseline HVPG ≥12 mmHg                          | No significant improvement in HVPG or clinical outcomes in patients with NASH-related cirrhosis and severe portal hypertension | Phase 2; recruitment status: completed                                                     |
| Emricasan                          | Caspase inhibitor       | NCT03205345       | Subjects with decompensated NASH cirrhosis                                               | Safe but ineffective for treatment of decompensated NASH cirrhosis                               | Phase 2; recruitment status: unknown                                                      |
| GS-9450                            | Caspase inhibitor       | NCT01703260       | Patients with elevated ALT (>60 U/L at screening), fatty liver on screening ultrasound, and biopsy-proven NASH | Significant reductions in ALT levels in NASH patients with GS-9450 treatment groups           | Phase 2; recruitment status: completed                                                     |
| Obeticholic acid (REVERSE)         | FXR agonist            | NCT03439254       | Subjects with a confirmed diagnosis of NASH and a fibrosis score of 4 based upon the NASH CRN | No results available                                                                            | Phase 3; recruitment status: active, not recruiting                                      |

(Continued on following page)
TABLE 1 (Continued) Clinical trials of medications associated with HSCs for NASH.

| Medication           | Primary mechanism | Trial number | Major inclusion criteria                                                                 | Outcome(s)                                                                 | Status                                                                 |
|----------------------|-------------------|--------------|------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------|
| Obeticholic acid     | FXR ligand        | NCT02548351  | Patients with definite NASH, NAFLD activity score of at least 4, and fibrosis stage F2-F3, or F1 with at least one accompanying comorbidity | Obeticholic acid 25 mg improved fibrosis and key components of NASH disease among patients with NASH | Phase 3; recruitment status: active, not recruiting                    |
| Tropifexor           | FXR agonist       | NCT02855164  | NASH on biopsy with stage 1–3 fibrosis or clinical risks for NASH                          | Anti-inflammatory and anti-steatogenic effects were observed in part A/B of a phase 2 trial. A significant reduction in ALT levels, weight loss, and liver fat loss according to the interim analysis in Part C. Adverse effects: pruritus, elevated LDL and decreased HDL. | Phase 2; recruitment status: terminated                                |
| Cenicriviroc         | CCR2/CCR5 inhibitor| NCT03028740  | Subjects with NASH and stage F2 or F3 fibrosis                                           | No results available                                                        | Phase 3; recruitment status: terminated (This study was terminated early due to lack of efficacy based on the results of the planned interim analysis of part 1 data.) |
| Simtuzumab (SIM, GS-6624) | LOXL2 inhibitor | NCT01672879  | Patients with bridging fibrosis caused by NASH                                           | Ineffective in decreasing hepatic collagen content or HVPG                  | Phase 2; recruitment status: terminated                                |
| ND-L02-s0201 Injection | HSP47 inhibitor  | NCT02227459  | Moderate to extensive hepatic fibrosis (META VIR F3-4)                                    | No results available                                                        | Phase 1; recruitment status: completed                                |
| IMM-124E             | Anti-LPS          | NCT02316717  | Diagnosis of NASH                                                                        | No significant improvement in clinical endpoints                             | Phase 2; recruitment status: completed                                |
| Liraglutide          | GLP-1 agonist     | NCT02654665  | Obese adults with non-alcoholic fatty liver disease                                      | Effective for decreasing weight, hepatic steatosis, and hepatocellular apoptosis in obese adults with NAFLD | Phase 3; recruitment status was: recruiting                              |
| Semaglutide          | GLP-1 agonist     | NCT02970942  | NASH on biopsy with stage 1–3 fibrosis                                                  | Significant improved NASH, but no improvement in fibrosis                  | Phase 3; recruitment status: completed                                |
| Tirzepatide          | Dual GIP/GLP1 agonist | NCT04166773 | Diagnosis of NASH                                                                        | No results available                                                        | Phase 2; Recruitment Status: recruiting                                |
| BI436906             | Dual GIP/GLP1 agonist | NCT04771273 | Diagnosis NASH and fibrosis stage F1-F3                                                   | No results available                                                        | Phase 2; Recruitment Status: recruiting                                |

HSC, hepatic stellate cell; NASH, non-alcoholic steato hepatitis; PPAR, peroxisome proliferator-activated receptor; SAF: A score, the activity part of the steatosis, activity, and fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation, ASK-1, apoptosis signaling kinase-1; PDE4, cyclic nucleotide phosphodiesterase 4; ALT, alanine amino transferase; CRN, clinical research network; HVPG, hepatic venous pressure gradient; FXR, Farnesoid X receptor; NAFLD, non-alcoholic fatty liver disease; CCR2/CCR5, the C–C motif chemokine receptor 2 (CCR2)–CCR5; LOXL2, lysyl oxidase-2; HSP47, heat shock protein 47; LPS, lipopolysaccharide; GLP-1, glucagon-like peptide 1; GIP, glucose-dependent insulinotropic polypeptide.

exogenous ACE2 or increasing its endogenous expression may serve as new targets for NAFLD. Oral treatment with Ang1-7 improves inhibiting liver inflammation in high-fat diet-fed rats (Santos et al., 2013).

In short, the progression of liver fibrosis involves multiple events, of which the activation of HSCs is publicly recognized as the central element. Activated HSCs respond to the stimulus from the intracellular and extracellular microenvironment by interacting with other cells, thereby triggering wound-healing. Through diverse molecular mechanisms and cell signaling, “responded” cells play dual roles in the activation of HSCs during different stages of fibrosis.

**Perspectives of pharmacotherapies on HSCs**

Since the mechanism underlying the NAFLD, which is a complicated and intricate process involving numerous risk factors, kinds of organs, different cell types, and the interplay of multiple signaling pathways, (Tilg and Moschen, 2010), has not been fully elucidated, there is no unified, clear, effective treatment for it currently. Lifestyle modification by dietary caloric restriction, exercise, and weight loss is the primary therapy for NAFLD. A loss of 5–7% of the initial weight within one year for patients with NAFLD is recommended,
while in patients with suspected NASH, the targeted needs to be increased to 7–10%. Fibrosis may be attenuated only in patients with a weight loss of ≥10% (Vilar-Gomez et al., 2015; Romero-Gómez et al., 2017). Unfortunately, most patients fail to meet the goal and benefit from lifestyle intervention due to the lack of compliance and poor self-control (Vilar-Gomez et al., 2015). Surgical treatment for NAFLD mainly includes bariatric surgery, also called metabolic surgery, and liver transplantation. Studies have showed that bariatric surgery can not only improve the histological features of NASH with fibrosis or compensated cirrhosis but also reduced the risk of cardiovascular events effectively (Maciejewski et al., 2016; Ikramuddin et al., 2018; Aminian et al., 2019). As for liver transplantation, it remains the only possible intervention in end-stage liver disease or hepatocellular carcinoma related to NASH (Chalasani et al., 2018). But considering the high recurrence rate, prohibitive risk, and high cost, the application of the surgery has been limited clinically.

Taking all these into consideration, clinically effective and safe pharmacological treatments are in great demand (see Figure 3). Medication development should be based on drug targets and the mechanism of action. Given the significant role of HSCs in this pathological process from the perspective of inflammation and fibrosis, the medical therapies for NAFLD associated with HSCs are focused on here (see Table 1).

Peroxisome proliferator-activated receptor (PPAR) belongs to nuclear receptor superfamily and comprises three forms: PPARα, PPARβ/δ, and PPARγ involving in modulating lipid metabolic homeostasis (Oh and Ahn, 2021). It has been introduced that PPARs can modulate HSC activation though defending against lipid-related toxicity and mitigate hepatocyte stress (Bojic and Huff, 2013; Pawlak et al., 2015). However, clinical studies are yet to validate their effects on fibrosis related to NASH. Pioglitazone, a PPARγ-specific agonist; elafibranor, a dual PPARαβ/δ agonist; and lanifibranor, a PPARαβ/γ/δ are all under clinical trials (Sanyal et al., 2010; Ratziu et al., 2016; Francque et al., 2021).

As is known, hepatocyte apoptosis aggravates inflammatory response, and apoptotic bodies can activate HSCs and promote their transition to myofibroblasts, which enhance fibrogenesis (Canbay et al., 2003). Apoptosis signa-regulating kinase 1 (ASK-1), a member of MAP kinases (MAP3K), is expressed by inflammation and HSCs. Also, it can cause apoptosis and increase the expression of the proinflammatory and profibrotic cytokine in response to various stressors in turn (Schuster and Feldstein, 2017). Therefore, the inhibitor of ASK1—selsorsertib, can ameliorate NASH in some patients in a 24-week clinical trial (Loomba et al., 2018). Nevertheless, the outcomes are not satisfied in phase 3 trials (Harrison et al., 2020a). Emiracasan, a caspase inhibitor, has the effects similar to those of selonsertib (Harrison et al., 2020b; Garcia-Tsao et al., 2020).

Pentoxifylline (PTX), a cyclic nucleotide phosphodiesterase 4 (PDE4) inhibitor, had been proven in numerous research studies to inhibit the proliferation and activation of HSCs either by direct or indirect ways (Desmoulière et al., 1999; Gonzalo et al., 2006; Verma-Gandhu et al., 2007). PTX improved hepatic aminotransferases and inflammatory markers in Egyptian NASH patients in the clinical trials (Fouda et al., 2021). In addition, ASP9831 and rolumillust both belong to the PDE4 inhibitor.

C-C motif chemokine receptors 2 and 5 (CCR2 and CCR5) can promote the activation and migration of Kupffer cells and HSCs and increase inflammatory cells (Friedman et al., 2016), and thus the dual CCR2/CCR5 inhibitor CVC can reduce fibrosis progression to some extent, which was evident in animal models (Lebvre et al., 2016). Unfortunately, it showed no significant effect in phase 3 clinical trial (Anstee et al., 2020).

Farnesol X receptor (FXR) plays a vital role in regulating cholesterol and bile acid metabolism, and it can be expressed by HSCs and other kinds of cells associated with enterohepatic circulation. The activating FXR inhibited hepatic inflammation and fibrosis (Verbeke et al., 2016). Obeticholic acid (OCA), an FXR agonist, prevents the activation of HSCs and reduces the fiber generates related to protein, such as Col1a1, α-smooth muscle actin, and tissue inhibitors of metalloproteinases-1,-2, significantly contributing to the improvement in liver fibrosis (Zhou et al., 2020). Phase 3 clinical trials confirmed this positive effect on fibrosis, while accompanied with adverse effects including pruritus and elevation of low-density lipoprotein (Younossi et al., 2019). Tropifexor is another FXR agonist under reaserch.

Activated HSCs express high level of lysyl oxidase-like 2 (LOXL2) (Brovold et al., 2020), a key stromal enzyme in collagen formation. It can modify the extracellular matrix by promoting the cross-linking of collagen fibers resulting in the exacerbation of fibrosis, which can activate HSCs in turn. The inhibitory antibody against LOXL2, simtuzumab (previously known as GS-6624), was expected to mitigate this vicious circle in NASH. But it failed to perform well clinically (Harrison et al., 2018). Heat shock protein 47 (HSP47), a chaperone protein, is involved in regulating the folding of fibrillary collagens. Inhibiting this molecule causes collagen to misfold within the cell and to accumulate rather than secrete, resulting in HSC death eventually. Currently, a trial of liposomal formulation is under way in patients with advanced fibrosis. This study involved silencing HSP47 by siRNA to promote the apoptosis of HSCs (NCT02227459).

In addition, targeting intestinal lipopolysaccharide (LPS) can also obtain the anti-inflammatory and antifibrotic effects, for instance, IMM124E (Mizrahi et al., 2012). Although many pharmacotherapies on HSCs for NAFLD patients are introduced, most of them are only in the clinical trial stage.
and their safety and efficacy need to be further demonstrated. Given these, there are still no specific agents that are approved by the Food and Drug Administration (FDA) currently (Sheka et al., 2020). Therefore, the combination of drugs with different targets and integrated treatment of traditional Chinese medicine and Western medicine will be the key direction for future investigations.

Conclusion

Although HSCs comprise only a small proportion of hepatic cells, HSCs and their activation or inactivation appear to play a vital role in the development of NASH-induced hepatic fibrosis in NAFLD. Also, from the perspectives of inflammation and fibrosis, a deeper understanding of HSCs and the mechanisms leading to the investigation in NASH is, therefore, necessary if efforts are to identify potential HSC targets for drug development. Future studies are required to truly appreciate whether and how HSCs contribute to hepatic pathophysiology in NAFLD.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author contributions

CL and JD conceived the idea and designed the review. MW and LL wrote the manuscript. YX took part in the revision of the manuscript.

Funding

This study was financially supported by National Natural Science Foundation of China (Grant No. 820714351).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Allen, A. M., Van Houten, H. K., Sangaralingham, L. R., Talwalkar, J. A., and McCoy, R. G. (2018). Healthcare cost and utilization in nonalcoholic fatty liver disease: Real-world data from a large U.S. Claims database. Hepatology 68 (6), 2230–2238. doi:10.1002/hep.30094

Aminian, A., Zaizhchik, A., Arterburn, D. E., Wolski, K. E., Berthauer, S. A., Schauer, P. R., et al. (2019). Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 322 (13), 1271–1282. doi:10.1001/jama.2019.14231

Anzot, Q. M., Neuschwander-Tetri, B. A., Wong, V. W. S., Abdelmalek, M. F., Younossi, Z. M., Yuan, J., et al. (2020). Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design. Contemp. Clin. Trials 89, 105922. doi:10.1016/j.cct.2019.105922

Bataller, R., and Brenner, D. A. (2005). Liver fibrosis. J. Clin. Invest. 115 (2), 209–218. doi:10.1172/JCI24282

Bojic, L. A., and Huff, M. W. (2013). Peroxisome proliferator-activated receptor & a multifaceted metabolic player. Curr. Opin. Lipidol. 24 (2), 171–177. doi:10.1097/MOL.0b013e32835c494

Brandl, K., and Schnabl, B. (2017). Intestinal microbiota and nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol. 33 (3), 128–133. doi:10.1097/MOG.0000000000000349

Branikov, M., Jovankovic, I., Djukić, M., Radojčić, T., Opršć, S., Klasnja, S., et al. (2022). Lipotoxicity as the leading cause of non-alcoholic steatohepatitis. Int. J. Mol. Sci. 23 (9), 5146. doi:10.3390/ijms23095146

Breuer, D. A., Pacheco, M. C., Washington, M. K., Montgomery, S. A., Hasty, A. H., and Kennedy, A. J. (2020). CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 318 (2), G211–G224. doi:10.1152/ajpgi.00040.2019

Brovold, M., Keller, D., and Sokr, S. (2020). Differential fibrilotic phenotypes of hepatic stellate cells within 3D liver organoids. Biotechnol. Bioeng. 117 (8), 2516–2526. doi:10.1002/bit.27379

Browning, J. D., and Horton, J. D. (2004). Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2), 147–152. doi:10.1172/JCI212422

Canbay, A., Taimr, P., Torok, N., Higuchi, H., Friedman, S., and Gores, G. J. (2003). Apoptotic body engulfment by a human stellate cell line is pro-fibrogenic. Lab. Invest. 83 (5), 655–663. doi:10.1097/01.lab.0000069036.63405.5c

Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Krauf, C., Bastelica, D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (New York, N.Y.) 56 (7), 1761–1772. doi:10.2337/db06-1491

Causse, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., et al. (2019). A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat. Commun. 10 (1), 1406. doi:10.1038/s41467-019-09455-9

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinel, M., et al. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67 (1), 328–357. doi:10.1002/hep.29356

Cohen, J. C., Horton, J. D., and Hobbs, H. H. (2011). Human fatty liver disease: Old questions and new insights. Science 332 (6037), 1519–1523. doi:10.1126/science.1204265

Desmoulière, A., Xu, G., Desmouliere, A., Yousef, I. M., Gabbanini, G., and Tuchwell, B. (1999). Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. J. Hepatol. 30 (4), 621–631. doi:10.1016/S0168-8278(99)80192-5

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., et al. (2017). Cenicriviroc for the treatment of liver fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65 (5), 1557–1565. doi:10.1002/hep.29085

Funding

This study was financially supported by National Natural Science Foundation of China (Grant No. 820714351).

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 13 (9), 509–520. doi:10.1038/nrendo.2014.76

Miele, L., Valenzia, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. (2009). Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (6), 1877–1887. doi:10.1002/hep.22884

Mirzaii, M., Shahb, Y., Ben Yaacov, A., Lalazar, G., Adar, T., Wong, V., et al. (2012). Alleviation of insulin resistance and liver damage by oral administration of imm124-E is mediated by increased tregs and associated with increased serum GLP-1 and adiponectin: results of a phase 1/1 clinical trial in NASH. J. Hepatol. 53 (1), 192–200. doi:10.1016/j.jhep.2010.11.014

Newcombe, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., et al. (2021). A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384 (12), 1113–1124. doi:10.1056/NEJMoa2028395

Oh, J. M., and Ahn, B. C. (2021). Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 11 (13), 6251–6277. doi:10.7150/thno.57569

Pawlak, M., Lefebvre, P., and Staels, B. (2015). Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. Hepatology 62 (3), 720–733. doi:10.1002/hep.27450

Peverill, W., Powell, L. W., and Skoien, R. (2014). Evolving concepts in the pathogenesis of NASH beyond steatosis: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 11 (13), 6251–6277. doi:10.7150/thno.57569

Potter, J. J., Rennie-Tankesley, L., and Mezey, E. (2003). Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration. J. Hepatol. 38 (3), 281–288. doi:10.1016/S0168-8278(03)00412-4

Hite, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., and Davies, M. J. (2017). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed treatment comparison analysis. Diabetes Obes. Metab. 19 (4), 524–536. doi:10.1111/dme.12631

Ikrumuddin, S., Kornier, J., Lee, W. J., Thomas, A. J., Connell, J. E., Bandle, J. P., et al. (2018). Lifestyle intervention and medical management with vs without roux-en-y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 Years in the diabetes surgery study. JAMA 319 (3), 266–278. doi:10.1001/jama.2017.08031

Kamm, D. R., and McConniss, K. S. (2022). Hepatostellate cells in physiology and pathology. J. Physiol. 600 (8), 1825–1837. doi:10.1113/jphysiol.2021281064

Kawano, Y., and Cohen, D. E. (2013). Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J. Gastroenterol. 48 (4), 434–441. doi:10.1038/jgs.2013.7-0358-8

Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., et al. (2012). Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. U. S. A. 109 (24), 9488–9493. doi:10.1073/pnas.1201840109

Lefebvre, E., Myorge, R., Reshet, R., Richman, L. P., Thompson, M., Hong, F., et al. (2016). Antibiotic effects of the dual CCR2/CXCR3 antagonist canacinrivir in animal models of liver and kidney fibrosis. PLoS One 11 (6), e0151856. doi:10.1371/journal.pone.0151856

Loomer, R., Lautz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., et al. (2018). The ASKr inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology 67 (2), 549–559. doi:10.1002/hep.29514

Lotze, M. T., Zeh, H. J., Rubartelli, A., Sparvero, J. I., Amosco, A. A., Washburn, N. R., et al. (2007). The grateful dead damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunity 20, 60–81. doi:10.1016/j.immuni.2007.05.007.x

Luedde, T., Kaplowitz, N., and Schwabe, R. F. (2014). Cell death and cell death responses in liver disease: Mechanisms and clinical relevance. Gastroenterology 147 (4), 765–783. doi:10.1053/j.gastro.2014.07.018

Maciejewska, M. L., Arterburn, D. E., Van Scyoc, L., Smith, V. A., Yancy, W. S., Weidenhacher, H. J., et al. (2016). Bariatric surgery and long-term durability of weight loss. JAMA Surg. 151 (11), 1046–1055. doi:10.1001/jamasurg.2016.2317

Mage, N., Zou, A., and Zhang, Y. (2016). Pathogenesis of nonalcoholic steatohepatitis: Interactions between liver parenchymal and nonparenchymal cells. Biomed. Res. Int. 2016, 5170402–5170411. doi:10.1155/2016/5170402

Marcher, A., Bendixen, S. M., Terkelsen, M. K., Hohnmann, S. S., Hansen, M. H., Larsen, B. D., et al. (2019). Transcriptional regulation of hepatic stellate cell activation in NASH. Sci. Rep. 9 (1), 2324. doi:10.1038/s41598-019-39112-6

Meex, R. C. R., and Watt, M. J. (2017). Hepatocines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 13 (9), 509–520. doi:10.1038/nrendo.2017.56

Miele, L., Valenzia, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. (2009). Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (6), 1877–1887. doi:10.1002/hep.22884

Mizrahi, M., Shabat, Y., Ben Yaacov, A., Lalazar, G., Adar, T., Wong, V., et al. (2012). Alleviation of insulin resistance and liver damage by oral administration of imm124-E is mediated by increased tregs and associated with increased serum GLP-1 and adiponectin: results of a phase 1/1 clinical trial in NASH. J. Inflamm. Res. 5, 141–150. doi:10.2147/JIR.S31227

Newcombe, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., et al. (2021). A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384 (12), 1113–1124. doi:10.1056/NEJMoa2028395
Tariq, Z., Green, C. J., and Hodoon, L. (2014). Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Liver Int. 34 (7), e180–e190. doi:10.1111/liv.12523

Tilg, H., and Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (5), 1836–1846. doi:10.1002/hep.24001

Toblli, J. E., Mutur, M. C., Cao, G., Mella, J., Pereyra, L., and Mastai, R. (2008). ACE inhibition and AT1 receptor blockade prevent fatty liver disease in obese Zucker rats. Obes. (Silver Spring) 16 (4), 770–776. doi:10.1002/oby.2007114

Tuschida, T., and Friedman, S. L. (2017). Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14 (7), 397–411. doi:10.1038/nrgastro.2017.38

Trawinski, S., Sasaki, S., Akutou, T., Takamura, T., Igarashi, T., Yoshimoto, M., et al. (2022). Positive pattern recognition system using alamine aminotransferase, type IV collagen βs, and E value (liver stiffness) for the diagnosis of nonalcoholic steatohepatitis based on natural history. Based Nat. Hist. 5, 238–239. doi:10.31662/ jmai.2021-0199

Verbeke, I., Mannarets, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, L., et al. (2016). FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci. Rep. 6, 33453. doi:10.1038/srep33453

Verjui, G., Barbui, V., Lemoine, M., Wendum, D., Chatzantoniou, C., Serfati, L., et al. (2011). progression of NAFLD in humans is associated with the activation of the renin-angiotensin system. J. Hepatol. 54, 5348. doi:10.1016/s0168-8278(11)60875-1

Verma-Gandhu, M., Petersen, M. R., and Peterson, T. C. (2007). Effect of fetuin, a TGFβ1 antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis. Eur. J. Pharmacol. 572 (2–3), 220–227. doi:10.1016/j.ejphar.2007.06.039

Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., et al. (2015). Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149 (2), 307–318. doi:10.1053/j.gastro.2015.04.005

Wagner, M., Zollner, G., and Trauner, M. (2011). Nuclear receptors in liver disease. Hepatology 53 (3), 1023–1034. doi:10.1002/hep.24148

Wang, A., Zhang, F., Xu, H., Xu, M., Cao, Y., Wang, C., et al. (2017). TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-kB/STAT3 pathways. Mol. Immunol. 87, 67–75. doi:10.1016/j.molimm.2017.04.003

Wex, Y., Clark, S. E., Thyfault, J. P., Upptegrove, G. M. E., Li, W., Whalley-Connell, A. T., et al. (2009). Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic REN2 rats. Am. J. Pathol. 174 (4), 1329–1337. doi:10.2353/ajpath.2009.080697

Wree, A., Broderick, L., Canbay, A., Hoffmann, H. M., and Feldstein, A. E. (2013). From NASH to cirrhosis–new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10 (11), 627–636. doi:10.1038/nrgastro.2013.149

Yang, M., Ma, X., Xuan, X., Deng, H., Chen, Q., and Yuan, L. (2020). Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system. Front. Pharmacol. 11, 432. doi:10.3389/fphar.2020.00432

Yoshii, H., Noguchi, R., Ikenna, Y., Namiski, T., Kitade, M., Kaji, K., et al. (2009). Lisartin, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res. Notes 2, 70. doi:10.1186/1756-0500-7-20

Younossi, Z. M., Ratziv, V., Loomba, R., Minnelli, M., Anstee, Q. M., Goodman, Z., et al. (2019). Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394 (10215), 2184–2196. doi:10.1016/S0140-6736(19)33041-7

Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., et al. (2020). SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nat. Commun. 11 (2), 240. doi:10.1038/s41467-019-14138-6

Zisser, A., Ipsen, D. H., and Tveden-Nyborg, P. (2021). Hepatic stellate cell activation and inactivation in NASF-fibrosis—roles as putative treatment targets? Biomedicines 9 (4), 365. doi:10.3390/biomedicines9040365